ACTON, Mass. — Insulet Corporation has named Mike Panos as executive vice president and chief commercial officer, effective immediately, the company announced.
Panos will lead Insulet’s global commercial organization and report to President and Chief Executive Officer Ashley McEvoy. He will also join the company’s executive leadership team.
“We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” McEvoy said. “We are implementing thoughtful strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in building high-performing sales organizations and driving execution excellence will help elevate our commercial capabilities as we accelerate our growth.”
Panos brings about 30 years of commercial leadership experience in the medical technology sector. He most recently served as leader of sales excellence at Stryker Corporation, where he spent three decades in a range of senior roles, including president of the trauma and extremities division and president of North America and global research and development.
Throughout his career, Panos has built and scaled sales organizations, expanded market reach, and delivered sustained double-digit growth in competitive markets. He is also known for developing talent and leading large global teams to drive both revenue growth and operational performance.
A graduate of Boston College and a longtime Boston-area resident, Panos brings regional ties to Insulet’s Massachusetts-based operations.
At Insulet, he will oversee global commercial strategy and execution, with a focus on expanding market access, strengthening organizational capabilities, and supporting growth across new patient populations and care settings.
“I am honored to join Insulet at such a pivotal time in its journey,” Panos said. “Insulet has built a strong foundation, with differentiated technology, compelling clinical outcomes, and a powerful brand. With significant opportunity to expand globally and reach more people with diabetes — including those not yet benefiting from automated insulin delivery technology — I look forward to partnering with the team to further strengthen commercial execution, support providers and patients, and help realize the full potential of the Omnipod platform.”
